Welcome to our dedicated page for Omeros news (Ticker: OMER), a resource for investors and traders seeking the latest updates and insights on Omeros stock.
Omeros Corporation develops and commercializes protein and small-molecule therapeutics for large-market and orphan indications, with emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its news centers on YARTEMLEA (narsoplimab-wuug), an FDA-approved MASP-2 lectin pathway inhibitor for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adult and pediatric patients aged two years and older.
Recurring updates also cover U.S. commercialization, reimbursement coding, transplant-medicine presentations, operating and financial results, and pipeline work including OMS1029, a long-acting MASP-2 inhibitor, and OncotoX-AML, an oncology therapeutic platform targeting acute myeloid leukemia.
Omeros (Nasdaq: OMER) reported second‑quarter 2026 net product sales of $28.5 million, all from YARTEMLEA, whose gross revenue rose 190% quarter‑over‑quarter to $32.2 million from $11.1 million. Gross‑to‑net adjustments were about 11.5%.
GAAP net income was $13.2 million, or $0.18 per diluted share, versus a $25.4 million loss a year earlier, aided by an $11.5 million non‑cash gain from 2029 note remeasurement. Non‑GAAP adjusted net income was $1.8 million ($0.02 per share), compared with a $17.1 million loss in first‑quarter 2026.
Omeros ended June 30, 2026 with $132.0 million in cash and short‑term investments and generated $4.1 million of operating cash in the quarter. The company repurchased $30.5 million principal of its 2029 notes for $60.2 million, cutting remaining principal to $40.3 million, eliminating $8.6 million of future interest and reducing potential dilution by about 5 million shares. Omeros also bought back 0.5 million shares in Q2 and 0.8 million year‑to‑date at an average $11.70 per share.
Omeros (NASDAQ: OMER) will release its financial results for the second quarter of 2026 on Wednesday, August 12, 2026, after market close. Management will hold a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) the same day to review recent developments, highlights, and the quarter’s financial performance.
Investors can access the live webcast via the “Upcoming Events” section of the Omeros Investor Relations website, with a replay available for 90 days in “Archived Events.” According to the company, Omeros is transitioning to a new earnings call platform hosted by Q4, and participants are advised to allow extra time to log in.
Omeros (Nasdaq: OMER) announced that the Centers for Medicare & Medicaid Services granted New Technology Add-On Payment (NTAP) status for YARTEMLEA (narsoplimab-wuug) in the FY 2027 Hospital Inpatient Prospective Payment System Final Rule. Effective October 1, 2026, eligible U.S. hospitals treating Medicare patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) using YARTEMLEA will receive up to $287,079 in additional Medicare reimbursement per eligible inpatient.
According to Omeros, NTAP payments go to hospitals and do not change the amount it receives for YARTEMLEA. YARTEMLEA is described as the first and only FDA-approved treatment for TA-TMA and the only approved inhibitor of the lectin pathway of complement, targeting MASP-2. The company highlights its broader pipeline in complement-mediated diseases, oncology, and addictive disorders.
Omeros (Nasdaq: OMER) reported that EMA’s CHMP issued a negative opinion on its MAA for narsoplimab (YARTEMLEA) in TA-TMA. The company plans to request re-examination and AHEG review.
YARTEMLEA received FDA approval in December 2025 for TA-TMA patients ≥2 years and is supplied via a global compassionate use program.
Omeros (Nasdaq: OMER) will host a live webcast of its virtual Annual Meeting of Shareholders on Thursday, June 18, 2026, at 10:00 a.m. Pacific Time via www.virtualshareholdermeeting.com/OMER2026.
Only shareholders of record as of April 17, 2026 may vote; a replay will be available on the investor relations website.
Omeros (Nasdaq: OMER) reported first-quarter 2026 results, driven by the January U.S. launch of YARTEMLEA. Gross product sales were $11.1 million, with net sales of $9.9 million. Reported net income was $56.1 million ($0.78/share), including a $73.1 million non-cash gain from 2029 note derivatives; non-GAAP adjusted net loss was $17.1 million ($0.24/share). Cash and short-term investments totaled $135.3 million. The company fully repaid its 2026 notes and now has $70.8 million of 2029 notes outstanding. CMS assigned a permanent J-code for YARTEMLEA effective July 1, 2026, and proposed NTAP status, with a final decision expected in August and potential effectiveness October 1, 2026. EMA review of the YARTEMLEA MAA continues with a mid-2026 decision expected.
Omeros (NASDAQ: OMER) will release its first quarter 2026 financial results on Wednesday, May 13, 2026, after market close.
Management will host a conference call and webcast at 4:30 p.m. ET to review recent developments and financial results, with a replay available for 90 days.
Omeros (NASDAQ: OMER) said CMS assigned a permanent HCPCS J-code (J1289) for YARTEMLEA, effective July 1, 2026. The product-specific code aims to simplify billing and reimbursement for Medicare, other U.S. government programs and commercial payors, and to align with ICD-10-CM M31.11 for TA-TMA.
The company highlighted that the J-code should reduce administrative burden, support faster patient access, and provide more predictable reimbursement for providers; patient support is available via YARTEMLEAssist and a dedicated phone line.
Omeros (Nasdaq: OMER) reported Q4 and full-year 2025 results on March 31, 2026, driven by a $237.6M net gain from the sale of zaltenibart to Novo Nordisk and an FDA approval.
Q4 net income was $86.5M ($1.22/share); 2025 net loss was $3.4M ($0.05/share). Cash and short-term investments: $171.8M; debt principal: $87.9M.
Omeros (NASDAQ: OMER) will report fourth-quarter and full-year 2025 financial results on March 31, 2026 after market close.
Management will host a conference call and webcast the same day at 4:30 p.m. ET (1:30 p.m. PT). A replay will be available for 90 days. The company is transitioning to a new Q4 Inc. earnings platform; allow extra login time.